Jump to content
Objectivism Online Forum


Rate this topic


Recommended Posts

Adult stem cells show enormous theraputic potential for treating a large number of degenerative conditions. That promise is already being realized in several other countries whose governments are less hostile to biotech innovation, but in the U.S., their use remains utterly encumbered by the regulatory environment here. As a result, the U.S. is underperforming third-world shitcans like Mexico and Thailand in this vital new arena. To my amazement, Senator Mark Kirk (R-Ill), with a Democrat co-sponsor, recently introduced a bill titled the REGROW Act that would drastically reduce the regulatory barriers to patient access of regenerative medicine products. It would create an altogether new regulatory pathway for cell-based products, which, among other things, would include a 5-year "conditional approval" policy that would allow these treatments to be used immediately if they show strong prima facie evidence of safety and effectiveness. This would be a game-changer for the U.S. healthcare if it passes, which is why I'm thinking it won't. It's contradictory to the spirit of ObamaCare, with its reliance on strict government-imposed treatment guidelines, and I can't see the same people who had to cram the law down our throats so we could see what's in it supporting a law like this. 



Edited by dream_weaver
Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


  • Recently Browsing   0 members

    • No registered users viewing this page.
  • Create New...